Boehringer Ingelheim has a second positive trial under its belt for nerandomilast in pulmonary fibrosis, setting up regulatory filings. The new data from the 1,178-patient FIBRONEER-ILD study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback